Why Cullinan Therapeutics, Inc. (CGEM) stock fell 20.7% on Wednesday, November 4, 2026

Cullinan Therapeutics, Inc. (CGEM) closed at $12.49, down 20.70% on Wednesday, November 4, 2026, on volume of 2,201,440 shares (2.4× its 3-month average); market value about $800.0M.

What happened: primary sources

Events Nexqual found for CGEM on Wednesday, November 4, 2026 or the trading day before (November 3, 2026):

• Nov 4, 2026: SEC 8-K: Other material event source
  Quoted from the filing: “On November 4, 2026, the Company shared updated data from its Phase 1 dose escalation clinical trial for CLN-049 in patients with relapsed or refractory AML or MDS. As of the data cutoff, 87 patients (76 AML, 11 MDS) were enrolled across 13 cohorts (target dose range, 1.5-24 g/kg). The cytokine release syndrome ("CRS") rate was 36% (13/36 patients), which included the only Grade 3 event, in patients receiving one step-up dose. Implementation of a two step-up dosing regimen (1 or 1.5 g/kg to 6 g/kg) reduced CRS…”

These are listed as context. A filing or rating change on the same day is not proof that it caused the move; read the source.

More on CGEM

CGEM stock page: price, SEC financials, insider trades, superinvestor holders, analyst estimates and options. Other big moves that day: November 4, 2026.

Sources: SEC EDGAR, Nexqual Earnings Flash, analyst rating changes, Nexqual market data. Built November 10, 2026 at 16:46 UTC. Not investment advice.

Data source: Nexqual. Last updated: November 10, 2026 at 16:46 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt